Fluorodeoxyglucose (FDG) positron emission tomography (PET) in testicular germ cell tumours in adults: Preliminary French clinical evaluation, development of the technique and its clinical applications;Tomographie à émission de positons (T.E.P.) au fluorodéoxyglucose (F.D.G.) dans les tumeurs germinales testiculaires de l'adulte : Première évaluation clinique française, mise au point sur la technique et ses applications cliniques

Progres en Urologie

Volumn 10, Issue 6, 2000, Pages 1190-1199

  Maszelin, Philippe ^a,b   Lumbroso, Jean ^a   Theodore, Christine ^a   Foehrenbach, Hervé ^b   Merlet, Pascal ^c   Syrota, André ^c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b University of Paris Descartes   (France)

^c SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

Author keywords

Fluorodeoxyglucose; Germ cell tumour; Metastatic lymph nodes; Positron emission tomography; Testicular cancer

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EQUIPMENT DESIGN; FRANCE; GERM CELL TUMOR; HUMAN; INSTRUMENTATION; MALE; SCINTISCANNING; SEMINOMA; TESTIS TUMOR;

ADULT; EQUIPMENT DESIGN; FLUORODEOXYGLUCOSE F18; FRANCE; GERMINOMA; HUMANS; MALE; RADIOPHARMACEUTICALS; SEMINOMA; TESTICULAR NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034573841     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. ALBERS P., BENDER H., YILMAZ H., SCHOENEICH G., BIERSACK H.J., MUELLER S.C. : Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology, 1999, 53, 808-811.
2. AMROLIA P., SULLIVAN M.H.F., GARSIDE D., BALDWIN S.A., COOKE B.A. : An investigation of glucose uptake in relation to steroidogenesis in rat testis and tumour Leydig cells. Biochem. J., 1988, 249 : 925-928.
3. BACHOR R., KOCHER F., GROPENGIESSER F., RESKE S.N., HAUTMANN R.E. : Positron emission tomography : introduction of a new imaging technique for urological tumors and initial clinical results. Urologe A, 1995, 34, 138-142.
4. BENDER H., SCHOMBURG A., ALBERS P., RUHLMANN J., BIERSACK H.J. : Possible role of F.D.G.-P.E.T. in the evaluation of urologic malignancies. Anticancer Res., 1997, 17, 1655-1660.
5. BENDRIEM B., DE DREUILLE O. : Détection de positons : principes et instrumentation. R.B.M., Rev. Eur. Technol. Bioméd., 1998, 20, 114-122.
6. CREMERIUS U., EFFERT P.J., ADAM G., SABRI O., ZIMNY M., WAGENKNECHT G., JAKSE G., BUELL U. : F.D.G. P.E.T. for detection and therapy control of metastatic germ cell tumor. J. Nucl. Med., 1998, 39, 815-822.
7. CREMERIUS U., WILDBERGER J.E., BORCHERS H., ZIMNY M., JAKSE G., GUNTHER R.W., BUELLU. : Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer ? - Results of a study in 50 patients. Urology, 1999, 54, 900-904.
8. DE DREUILLE O., BRASSE D., BENDRIEM B., CORONE C., LAMER O., GAILLARD J.F., PECKING A. : Détection en coincidence sur gamma caméra conventionnelle : principes et performances. Méd. Nucl. I.F.M., 1999, 23, 81-92.
9. DI CHIRO G., DELAPAZ R.L., BROOKS R.A., SOKOLOFF L., KORNBLITH P.L., SMITH B.H., PATRONAS N.J., KUFTA C.V., KESSLER R.M., JOHNSTON G.S., MANNING R.G., WOLF A.P. : Glucose utilization of cerebral gliomas measurements by [18F]-fluorodeoxyglucose and positron emission tomography. Neurology, 1982, 32, 1323-1329.
10. GAMBHIR S.S., HOH C.K., PHELPS M.E., MADAR I., MADDAHI J. : Decision tree sensitivity analysis for cost-effectiveness of F.D.G.-P.E.T. in the staging and management of the non-small-cell lung carcinoma. J. Nucl. Med., 1996, 37, 1428-1436.
11. HOH C.K., SELTZER M.A., FRANKLIN J., DEKERNION J.B., PHELPS M.E., BELLDEGRUN A. : Positron emission tomography in urological oncology. J. Urol., 1998, 159, 347-356.
12. KOSUDA S., FISHER S., KISON P.V., WAHL R .L., GROSSMAN H.B. : Uptake of 2-deoxy-2-[18F]fluoro-D-glucose in the normal testis : retrospective PET study and animal experiment. Ann. Nucl. Med., 1997, 11, 195-199.
13. LANDONI C., GIANOLLI L., LUCIGNANI G., MAGNANI P., SAVI A., TRAVAINI L., FAZIO F. : Comparison of dual-head coincidence imaging PET versus conventional ring PET in tumors patients. Eur. J. Nucl. Med., 1999, 25, 379.
14. LEISURE G.P., VESSELLE H.J., FAULHABER P.P., O'DONNELL J.K., ADLER L.P., MIRALDI F.D. : Technical improvements in fluorine-18-F.D.G. P.E.T. imaging of the abdomen and pelvis. J. Nucl. Med. Technol., 1997, 25, 115-119.
15. MUGGIA F.M., CONTI P.S. : Seminoma and sarcoidosis : a cause for false positive mediastinal uptake in P.E.T. ?. Ann. Oncol., 1998, 9, 924.
16. MULLER-MATTHEIS V.G.O., REINHARDT M.J., GERHARZ C.D., FURST G., VOSBERG H.R., MULLER-GARTNER H.W., ACKERMANN R. : Positron emission tomography with [18F]-2-fluoro-2-deoxy-D-glucose (18F.D.G.-P.E.T.) in diagnosis of retroperitoneal lymph node metastases of testicular tumors. Urologe A, 1998, 37, 609-620.
17. NUUTINEN J.M., LESKINEN S., ELOMAA I., MINN H., VARPULA M., SOLIN O., SODERSTROM K.O., JOENSUU H., SALMINEN E. : Detection of residual tumours in postchemotherapy testicular cancer by F.D.G.-P.E.T., Eur. J. Cancer., 1997, 33, 1234-1241.
18. PHELPS M.E., HUANG S.C., HOFFMAN E.J., SELIN C., SOKOLOFF L., KUHL D.E. : Tomographic measurements of local cerebral glucose metabolic rate in humans with [F-18]-2-fluoro-2-deoxy-D-glucose : validation of method. Ann. Neurol., 1979, 6, 371-388.
19. REINHARD T.M.J. : Hodentumoren. In : P.E.T. in der klinischen onkologie. Wieler H.J., (Hrsg.). Darmstadt, Steinkopff, 1999, pp. 261-275.
20. REINHARD T.M.J., MULLER-MATTHEIS V.G.O., GERHARZ C.D., VOSBERG H.R., ACKERMANN R., MULLER-GARTNER H.W. : F.D.G.-P.E.T. evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy. J. Nucl. Med., 1997, 38, 99-101.
21. RIGO P., PAULUS P., JERUSALEM G., BURY T., DENEUFBOURG J.M., DEPAS G., BENOIT T., LAROCK M.P., FOIDART J. : Indications cliniques de la tomographie par émission de positons au 18F.D.G. en oncologie. Expérience préliminaire et revue de la littérature. Méd. Nucl. I.F.M., 1995, 19, 73-89.
22. SOKOLOFF L., REIVICH M., KENNEDY C. & coll. : The [14C]-deoxyglucose method for the measurement of local cerebral glucose utilization : theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem., 1077, 28, 897-916.
23. STEPHENS A.W., GONIN R., HUTCHlNS G.D., EINHORN L.H. : Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J. Clin. Oncol., 1996, 14, 1637-1641.
24. SUGAWARA Y., ZASADNY K.R., GROSSMAN H.B., FRANCIS I.R., CLARKE M.F., WAHL R.L. : Germ cell tumor - differentiation of viable tumor, mature teratoma, and necrotic tissue with F.D.G. P.E.T. and kinetic modeling. Radiology, 1999, 211, 249-256.
25. VESSELLE H.J., MIRALDI F.D. : F.D.G. P.E.T. of the retroperitoneum : normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics, 1998, 18, 805-823, discussion 823-824.
26. VUILLEZ J.P. : Métabolisme glucidique des cellules tumorales : conséquences pour l'utilisation de radio-pharmaceutiques analogues du glucose. Méd. Nucl. I.F.M., 1998, 22, 9-29.
27. WARBURG O., WIND F., NEGLERS E. : On the metabolism of the tumors in the body. In : Metabolism of tumors. Warburg O., (Ed.). London, Constable, 1930, pp. 254-270.
28. WEBER W.A., AVRIL N., SCHWAIGER M. : Relevance of positron emission tomography (P.E.T.) in oncology. Strahlenther Onkol., 1999, 175, 356-373.
29. WEBER W.A., NEVERVE J., SKLAREK J., ZIEGLER S.I., BARTENSTEIN P., KING B., TREUMANN T., ENTERROTTACHER A., KRAPF M., HAUSSINGER K.E., LICHTE H., PRAUER H.N., THETTER O., SCHWAIGER M. : Imaging of lung cancer with fluorine-18 fluorodeoxyglucose : comparison of a dual-head camera in coincidence mode with a full-ring positron emission tomography system. Eur. J. Nucl. Med., 1999, 26, 388-395.
30. WILSON C.B., YOUNG H.E., OTT R.J., FLOWER M.A., CRONIN B.E. PRATT B.E., MC CREADY V.R., HORWICH A. : Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography : prospects for detection and management. Eur. J. Nucl. Med., 1995, 22, 508-513.